- Home
- IMAB vs UNCY Comparison
IMAB vs UNCY Comparison
Compare IMAB & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- UNCY
- Stock Information
- Founded
- IMAB 2014
- UNCY 2016
- Country
- IMAB United States
- UNCY United States
- Employees
- IMAB N/A
- UNCY N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- UNCY Health Care
- Exchange
- IMAB Nasdaq
- UNCY Nasdaq
- Market Cap
- IMAB 73.9M
- UNCY 78.1M
- IPO Year
- IMAB 2020
- UNCY 2021
- Fundamental
- Price
- IMAB $1.31
- UNCY $0.59
- Analyst Decision
- IMAB Strong Buy
- UNCY Strong Buy
- Analyst Count
- IMAB 2
- UNCY 4
- Target Price
- IMAB $5.50
- UNCY $6.38
- AVG Volume (30 Days)
- IMAB 238.6K
- UNCY 889.6K
- Earning Date
- IMAB 05-15-2025
- UNCY 05-14-2025
- Dividend Yield
- IMAB N/A
- UNCY N/A
- EPS Growth
- IMAB N/A
- UNCY N/A
- EPS
- IMAB N/A
- UNCY N/A
- Revenue
- IMAB N/A
- UNCY N/A
- Revenue This Year
- IMAB N/A
- UNCY N/A
- Revenue Next Year
- IMAB N/A
- UNCY $1,422.24
- P/E Ratio
- IMAB N/A
- UNCY N/A
- Revenue Growth
- IMAB N/A
- UNCY N/A
- 52 Week Low
- IMAB $0.60
- UNCY $0.20
- 52 Week High
- IMAB $2.00
- UNCY $0.96
- Technical
- Relative Strength Index (RSI)
- IMAB 76.59
- UNCY 48.92
- Support Level
- IMAB $0.90
- UNCY $0.56
- Resistance Level
- IMAB $1.47
- UNCY $0.62
- Average True Range (ATR)
- IMAB 0.10
- UNCY 0.05
- MACD
- IMAB 0.04
- UNCY 0.00
- Stochastic Oscillator
- IMAB 74.07
- UNCY 71.50
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.